Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Breakthrough Bleeds
Breakthrough Bleeds
  • Overview
  • Real-world Data
  • Assessing Breakthrough Bleeding
  • MASAC & WFH Guidelines

Treatment guidelines for breakthrough bleeds

According to MASAC and WFH guidelines, patients and caregivers need to recognize and treat bleeds rapidly1,2

WFH guidelinesa:

  • Continue to reinforce that patients and caregivers should not take a watch-and-wait approach. Bleeds need to be treated promptly and fully1
  • Note that delayed treatment of bleeding is known to result in worse short- and long-term outcomes in patients with hemophilia1
  • Recommend treating a bleed promptly to:
Check mark icon

Improve bleed resolution1

Check mark icon

Impact the development and long-term progression of arthropathy1

Check mark icon

Reduce rebleeding1

aRefers to the 2020 WFH Guidelines for the Management of Hemophilia, 3rd edition.

Actor portrayal

Treatment conversation illustration

Consider these recommendations from MASAC and the WFH for the treatment of hemophilia A with inhibitors:

  • Despite effective prevention of bleeding episodes with emicizumab, clinicians and patients should still expect breakthrough bleeding3
  • Acute bleeds should be treated promptly3
  • Emicizumab is not intended to treat acute bleeds1

FVIII=factor VIII; ISTH=International Society on Thrombosis and Haemostasis; MASAC=Medical and Scientific Advisory Council; WFH=World Federation of Hemophilia.

Vial and needle icon

Now that you’ve seen the data and guidelines, see a treatment option that may be right for your patients that might experience breakthrough bleeds.

Explore a treatment option

MASAC Guidelines

Review MASAC guidelines that address key areas, including emergency care, treatment recommendations, and management issues concerning patients with hemophilia and other rare bleeding disorders.

Find out more
National Bleeding Disorders Foundation logo
World Federation of Hemophilia logo

WFH Guidelines

Get the latest information on treatments for hemophilia and rare bleeding disorders, approaches to treating these diseases, and clinical study results.

Browse resources

References:

  1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
  2. MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors. MASAC Document #274. Accessed December 19, 2022. https://www.hemophilia.org/sites/default/files/document/files/274_HomeAdministration.pdf
  3. MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed December 19, 2022. https://www.hemophilia.org/sites/default/files/document/files/268_Emicizumab.pdf
     
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US23HCP00113 January 2024

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials